ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. — Investor Relations & Filings
Anhui Anke Biotechnology (Group) Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and commercialization of biopharmaceutical products. The company focuses on genetic engineering, cell therapy, and precision medicine. Its core product portfolio includes recombinant human growth hormone (rhGH) marketed under the brand Ansomone, and recombinant human interferon alpha-2b known as Anterferon. Anke Bio also develops diagnostic reagents, including biochemical and molecular diagnostic kits, and provides services in the fields of oncology and reproductive health. The company maintains a strong emphasis on innovation through its dedicated R&D centers, aiming to provide advanced therapeutic solutions for growth disorders, viral infections, and various cancers. Its operations span the entire value chain from basic research to clinical application and market distribution.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 关于第三期限制性股票激励计划抗肿瘤事业部以外获授人员首次授予股票第三个解除限售期解除限售股份上市流通的提示性公告 | 2025-12-02 | Chinese | |
| 关于第三期限制性股票激励计划抗肿瘤事业部获授人员预留授予股票第一个解除限售期解除限售股份上市流通的提示性公告 | 2025-12-02 | Chinese | |
| 关于第三期限制性股票激励计划抗肿瘤事业部获授人员首次授予股票第一个解除限售期解除限售股份上市流通的提示性公告 | 2025-12-02 | Chinese | |
| 股东会网络投票工作制度（2025年11月） | 2025-11-25 | Chinese | |
| 董事会议事规则（2025年11月） | 2025-11-25 | Chinese | |
| 董事及高级管理人员离职管理制度（2025年11月） | 2025-11-25 | Chinese |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2025
15 filings
| |||||
| 35333785 | 关于第三期限制性股票激励计划抗肿瘤事业部以外获授人员首次授予股票第三个解除限售期解除限售股份上市流通的提示性公告 | 2025-12-02 | Chinese | ||
| 35333782 | 关于第三期限制性股票激励计划抗肿瘤事业部获授人员预留授予股票第一个解除限售期解除限售股份上市流通的提示性公告 | 2025-12-02 | Chinese | ||
| 35333777 | 关于第三期限制性股票激励计划抗肿瘤事业部获授人员首次授予股票第一个解除限售期解除限售股份上市流通的提示性公告 | 2025-12-02 | Chinese | ||
| 35333769 | 股东会网络投票工作制度（2025年11月） | 2025-11-25 | Chinese | ||
| 35333750 | 董事会议事规则（2025年11月） | 2025-11-25 | Chinese | ||
| 35333741 | 董事及高级管理人员离职管理制度（2025年11月） | 2025-11-25 | Chinese | ||
| 35333730 | 战略与投资委员会工作细则（2025年11月） | 2025-11-25 | Chinese | ||
| 35333724 | 董事和高级管理人员所持本公司股份及其变动管理制度（2025年11月） | 2025-11-25 | Chinese | ||
| 35333716 | 董事、高级管理人员薪酬管理制度(2025年11月) | 2025-11-25 | Chinese | ||
| 35333701 | 募集资金管理制度(2025年11月) | 2025-11-25 | Chinese | ||
| 35333689 | 累积投票制实施细则（2025年11月） | 2025-11-25 | Chinese | ||
| 35333681 | 董事会秘书工作细则(2025年11月） | 2025-11-25 | Chinese | ||
| 35333671 | 独立董事提名人声明与承诺（姚禄仕） | 2025-11-25 | Chinese | ||
| 35333663 | 关于董事会换届选举的公告 | 2025-11-25 | Chinese | ||
| 35333653 | 舆情管理制度（2025年11月） | 2025-11-25 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/55035/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=55035 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=55035 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=55035 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 55035}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. (id: 55035)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.